TOPADUR Pharma AG is a clinical-stage swiss biopharmaceutical start-up based in Schlieren, Zurich.
We strive for significant improvement of patients’ quality of life while providing sustainable high growth value for investors and employees.
The company has discovered the DualTOP™ technology platform consisting of new dual-acting drugs.
We developed an attractive portfolio of drug candidates to address high unmet needs in aging diseases.
Aging processes are characterized by a reduction in blood circulation and dysregulation in cell-cell communication. The misbalance of cGMP levels leads to diseases like chronic wounds, skin fibrosis, age-related macula degeneration, diabetic retinopathy, colorectal cancer, hair loss and skin aging.
TOPADUR designed new drugs that target the cGMP-Enzyme Regulation System. TOPADUR’s compounds regulate the activity of sGC and PDE5 enzymes to increase the level of cGMP. This ultimately enables blood circulation and corrects the insufficient cell-cell communication.
TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with Yonsei University and Juviv Inc.Read more
TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.Read more